Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study.

Purpose: The aim of this study was to assess the 12-month efficacy of intravitreal
bevacizumab (IVB) injection for occult choroidal neovascularization secondary to agerelated
macular degeneration.
Methods: In this retrospective, interventional case series, 68 treatment-naïve patients
with age-related macular degeneration, affected by subfoveal occult choroidal neovascularization
showing recent disease progression, were monitored during the IVB protocol.
The patients received 1 initial IVB injection (1.25 mg/0.05 mL), and they underwent further
retreatment on a monthly basis only when necessary, according to a standardized asrequired
regimen, until no significant signs of choroidal neovascularization activity were
present. Main outcome measures were the modifications in best-corrected visual acuity
and in central retinal thickness measured by optical coherence tomography.
Results: With respect to baseline, at the 12-month check, mean best-corrected visual
acuity increased from 0.82 to 0.45 logMAR (P 0.01) and mean central retinal thickness
decreased from 517.0 m to 306.5 m (P 0.01). To achieve these benefits, the required
mean IVB number was lowered from 3.87 in the first 6 months to 1.085 in the second 6 months.
A better final best-corrected visual acuity was correlated with greater best-corrected visual
acuity (P 0.005) and lesser central retinal thickness (P 0.05) at baseline.
Conclusion: In patients with age-related macular degeneration complicated by progressive
occult choroidal neovascularization, first-line IVB administration represents a
useful therapeutic option, especially considering its lower cost in comparison with
other antiangiogenic drugs.
RETINA 29:1227–1234, 2009